INS and diabetes mellitus: In contrast to previous stem cell-derived insulin-secreting cell products requiring further differentiation in vivo after transplantation (Kroon et al., 2008), these SC islets are terminally differentiated at the time of transplantation and have shown efficacy in diabetes reversal in vivo in rodent models (Pagliuca et al., 2014, Vegas et al., 2016).